KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

27.00 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

March 11, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

March 08, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

March 07, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Insiders Buying Dorian LPG And 2 Other Stocks ↗

January 17, 2024

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

Via Benzinga

KalVista Pharma: Q2 Earnings Insights ↗

December 07, 2023

Via Benzinga

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

March 06, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 27, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 26, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

February 20, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 16, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 15, 2024

Via Benzinga

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

February 15, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 14, 2024

Via Benzinga

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

February 14, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 14, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? ↗

February 13, 2024

Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 13, 2024

Via Benzinga

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

February 13, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Insiders Buying Monro And 3 Other Stocks ↗

February 09, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗

February 02, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

January 30, 2024

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying ↗

January 22, 2024

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.

Via Benzinga

Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks ↗

January 11, 2024

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Via Benzinga

$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

January 08, 2024

Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades.

Via Benzinga

Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying ↗

January 02, 2024

Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

Via Benzinga

KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology

December 20, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024 ↗

December 07, 2023

KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.